

DEPARTMENT OF HEALTH & HUMAN SERVICES

PUBLIC HEALTH SERVICE NATIONAL INSTITUTES OF HEALTH

FOR US POSTAL SERVICE DELIVERY:
Office of Laboratory Animal Welfare
6700B Rockledge Drive, Suite 2500, MSC 6910
Bethesda, Maryland 20892-6910
Home Page: http://grants.nih.gov/grants/olaw/olaw.htm

FOR EXPRESS MAIL:
Office of Laboratory Animal Welfare
6700B Rockledge Drive, Suite 2500
Bethesda, Maryland 20817
Telephone: (301) 496-7163
Facsimile: (301) 480-3387

May 12, 2023

Re: Animal Welfare Assurance A3195-01 [OLAW Case 5J]

Dr. Mary Klotman
Dean, School of Medicine and
Vice Chancellor for Health Affairs
Duke University Medical Center
Duke South Clinic – 200 Trent Drive
(b) (4) Davidson Building
Durham, NC 27710

Dear Dr. Klotman,

The Office of Laboratory Animal Welfare (OLAW) acknowledges receipt of your April 11, 2023 letter reporting an instance of noncompliance with the PHS Policy on Humane Care and Use of Laboratory Animals at the Duke University following up on an initial March 31, 2023 notification by telephone.

According to the information provided, this office understands that the Duke University Animal Care and Use Committee (ACUC) determined that instances of noncompliance occurred with respect to use of drugs beyond the post-puncture discard date. The final report states buprenorphine-SR was administered as pre- and post-surgical analgesia to ~225 mice after the manufacture labeled post-puncture discard-date. It is stated the buprenorphine SR was within the labeled expiration date, and all animals associated with the incident exhibited no signs of post-surgical pain/distress during monitoring. In response to the incident, the following corrective action plan was developed:

- The Principal Investigator received a post-approval monitoring visit and a comprehensive audit of their anesthesia and analgesia drug storage and monitoring process by the Duke Office of Animal Welfare Assurance (e.g., Duke IACUC administrative office) to ensure compliance.
- Refinements to the laboratory's drug monitoring process were made to ensure drugs are removed from use prior to their expiration or discard-date.
- Re-education of laboratory members on the refined drug monitoring process occurred.

Per the report, Duke IACUC reviewed the matter at the March 23, 2023 meeting and determined it to be reportable to OLAW. The committee found the corrective actions to be appropriate and no further actions were required.

It is noted that this research is associated with PHS-funding and/or other funding sources with OLAW oversight. Based on its assessment of this explanation, OLAW understands that the Duke University has implemented appropriate measures to correct and prevent recurrences of these problems and is now compliant with provisions of the PHS Policy.

We appreciate being informed of these matters and find no cause for further action by this Office.

Page 2 – Dr. Klotman May 12, 2023 OLAW Case A3195-5J

Sincerely,

Jacquelyn T.

Tubbs -S

Jacquelyn Tubbs -S

Date: 2023-05.12 08:09:05

Jacquelyn Tubbs, DVM, DACLAM

Senior Animal Welfare Program Specialist

Division of Compliance Oversight

Office of Laboratory Animal Welfare

cc: IACUC Contact



Duke University Durham, North Carolina 27705



Office of Animal Welfare Assurance Campus Mail: Hock Plaza Box 2724 US Mail: 2424 Erwin Road; Suite 606; Durham, NC 27705 Voice: 919.668.6720 Fax: 919.668.6725 https://myresearchpath.duke.edu/topics/conduct-research-animals

April 11, 2023

Duke University; Animal Welfare Assurance # D16-00123 (A3195-01)

Office of Laboratory Animal Welfare (OLAW) National Institutes of Health 6700B Rockledge Drive, Suite 2500, MSC 6910 Bethesda, MD 20892

Duke University, in accordance with PHS Policy IV.F.3., provides this report of an incident, which involved an animal activity conducted or supported with PHS-funds or other funds with OLAW oversight. This incident was reviewed and determined to be reportable by the Duke Institutional Animal Care & Use Committee (IACUC).

Reportable requirement: Serious deviation from the provisions of the Guide.

Preliminary report: A preliminary, verbal report was provided to Dr. Jacquelyn Tubbs by Anna Hampton (Duke University Office of Animal Welfare Assurance Director and IACUC Chair) on March 31, 2023.

Number of animals affected: Approximately 225 mice

Date: Identified February 2, 2023

Description, outcome, and actions taken: Buprenorphine SR was administered for pre- and post-surgical analgesia to approximately 225 mice after the manufacture labeled 28 post-puncture discard-date. The buprenorphine SR was within the labeled expiration date. All animals reached a surgical plane of anesthesia for the procedure and no signs of post-surgical pain or distress was identified in these animals during monitoring.

Corrective actions to prevent reoccurrence included:

- The Principal Investigator received a post-approval monitoring visit and a comprehensive audit of their anesthesia and analgesia drug storage and monitoring process by the Duke Office of Animal Welfare Assurance (e.g., the Duke IACUC administrative office) to ensure compliance.
- Refinements to the laboratory's drug monitoring process were made to ensure drugs are removed from use prior to their expiration or discard-date.
- Re-education of laboratory members on the refined drug monitoring process occurred.

Conclusion: The Duke IACUC completed its investigation and performed final review of the issue at the March 23, 2023 IACUC meeting. The Duke IACUC determined that the incident was reportable to regulatory, granting, and oversight bodies, where applicable. In addition, the IACUC determined that the corrective actions were appropriate and no further actions were necessary. The Duke IACUC considers this incident closed.

This item was reported to Duke grants management to ensure compliance with the terms and conditions of the grant or award.

The Duke University is committed to protecting the welfare of animals used in research and appreciates the guidance and assistance provided by OLAW in this regard. Should you have any questions regarding this report, please contact Anna Hampton, DVM, IACUC Chair at Anna.Hampton@Duke.edu or (b) (6)



Duke University Durham, North Carolina 27705



Office of Animal Welfare Assurance Campus Mail: Hock Plaza Box 2724

US Mail: 2424 Erwin Road; Suite 606; Durham, NC 27705

Voice: 919.668.6720 Fax: 919.668.6725

https://myresearchpath.duke.edu/topics/conduct-research-animals

Thank you for your consideration of this matter.

Sincerely,

(b) (6)

Dr. Mary E. Klotman
Duke University
Dean, School of Medicine
Vice Chancellor for Health Affairs
Institutional Official

McCoy, Devora (NIH/OD) [E]

From:

OLAW Division of Compliance Oversight (NIH/OD)

Sent:

Tuesday, April 18, 2023 9:21 AM

To:

Anna Hampton

Cc:

OLAW Division of Compliance Oversight (NIH/OD)

Subject:

RE: Duke OLAW Report (Assurance # A3195-01 / D16-00123)

Good morning Dr. Hampton,

Thank you for sending us this final report for case A3195-5J and we will send an official response soon.

Best, Devora

Devora McCoy, BS, MBA (pronunciation)
Program Analyst
Division of Compliance Oversight
Office of Laboratory Animal Welfare
National Institutes of Health

Phone: 301-435-2390

Email: devora.mccoy@nih.gov

From: Anna Hampton <anna.hampton@duke.edu>

Sent: Monday, April 17, 2023 8:01 PM

To: OLAW Division of Compliance Oversight (NIH/OD) <olawdco@od.nih.gov> Subject: [EXTERNAL] Duke OLAW Report (Assurance # A3195-01 / D16-00123)

Dear OLAW,

Please see the attached final report for Duke University (Assurance # A3195-01 / D16-00123).

Please do not hesitate to contact me if you have any questions or need additional information.

Anna

Anna Hampton, DVM, DACLAM, DACAW, CPIA
Director, Office of Animal Welfare Assurance
Chair, Institutional Animal Care and Use Committee
Duke University
2424 Erwin Road,
Durham, NC 27705

main, NC 27703

(b) (6)

Duke Animal Program Website

A3195-5J



Initial Report of Noncompliance

By: J. Tubbs

Date: 03-31-20	023	Time: 3:06pm
Name of Person reporting: Telephone #: Fax #: Email: Anna.Hamp	•	
Name of Institution: Duke Assurance number: A3195	-	n
Did incident involve PHS funded activity? TBD Funding component: Was funding component contacted (if necessary):		
What happened? PI used buprenorpohine SR after 28d puncture date, it was still unexpired but used after the puncture date. No observed pain and/distress.		
Species involved: Mice Personnel involved: Dates and times: Feb 20 Animal deaths: None	22	
Projected plan and schedule for correction/prevention (if known):		
Projected submission to OI 60-90d	LAW of final report from Instituti	ional Official:
OFFICE USE ONLY Case #		